GlycoMark (1,5-AG): What Your Number Changes About Your Treatment

What GlycoMark (1,5-AG) Actually Measures

GlycoMark quantifies 1,5-anhydroglucitol, a six-carbon sugar absorbed from food and maintained at a steady-state concentration in the blood. Under normal conditions, the kidneys reabsorb nearly all filtered 1,5-AG. But when plasma glucose rises above the renal threshold (roughly 180 mg/dL), glucose competes with 1,5-AG for tubular reabsorption, and 1,5-AG spills into the urine. The result: blood levels fall.

This inverse relationship makes 1,5-AG a real-time marker of glycemic excursions. A 2003 study published in Diabetes Care by Dungan et al. established that 1,5-AG correlates inversely with the frequency and magnitude of postprandial glucose peaks over the preceding 1 to 2 weeks [1]. HbA1c, by contrast, reflects a 2- to 3-month weighted average and cannot distinguish between a patient with steady 160 mg/dL glucose and one oscillating between 80 and 280 mg/dL. Both might carry an HbA1c of 7.0%.

The GlycoMark assay received FDA 510(k) clearance and uses an enzymatic method on standard chemistry analyzers [2]. No fasting is required, and results are available within hours. The reference range for adults without diabetes is typically 10.7 to 32.0 µg/mL, with values below 10 µg/mL indicating clinically significant postprandial hyperglycemia [1].

Why HbA1c Alone Misses the Problem GlycoMark Catches

HbA1c remains the cornerstone of diabetes monitoring, but it has blind spots. The American Diabetes Association (ADA) 2024 Standards of Care acknowledges that HbA1c "does not capture glycemic variability or hypoglycemia" and recommends supplemental metrics, including continuous glucose monitoring (CGM) data, for a complete picture [3].

GlycoMark fills a specific gap. A study by Mehta et al. (2012) in The Journal of Clinical Endocrinology & Metabolism demonstrated that among 206 patients with type 2 diabetes and HbA1c values between 6.5% and 8.0%, 1,5-AG levels varied more than threefold, revealing wide differences in postprandial control that HbA1c masked entirely [4]. Patients with identical HbA1c values of 7.2% had 1,5-AG levels ranging from 3.1 to 18.6 µg/mL.

This matters for treatment. Glycemic variability, independent of mean glucose, is associated with increased oxidative stress and endothelial dysfunction. A 2006 study by Monnier et al. in JAMA found that activation of oxidative stress in type 2 diabetes correlated more closely with glucose fluctuations (measured by mean amplitude of glycemic excursions, or MAGE) than with chronic sustained hyperglycemia [5]. GlycoMark provides a lab-accessible proxy for these fluctuations without requiring a CGM device.

The Treatment Decision Framework: What Your Number Triggers

A clinician interpreting your 1,5-AG result will pair it with your HbA1c to determine whether your current regimen adequately controls mealtime glucose spikes. Here is how the two markers interact to shape prescribing decisions.

1,5-AG above 10 µg/mL with HbA1c at target (below 7.0%): Glucose control is stable with minimal postprandial excursions. No medication change is typically needed. The current regimen is working across both fasting and mealtime windows.

1,5-AG below 10 µg/mL with HbA1c at target: This combination is the most actionable scenario. Despite an acceptable HbA1c, the patient is experiencing frequent glucose spikes above 180 mg/dL. The 2023 American Association of Clinical Endocrinology (AACE) consensus statement notes that postprandial hyperglycemia is a "cardiovascular risk factor independent of fasting glucose" and recommends targeting postprandial values below 180 mg/dL [6]. Treatment options at this stage include adding a rapid-acting insulin analog (lispro, aspart), starting an alpha-glucosidase inhibitor (acarbose), or initiating a GLP-1 receptor agonist with documented postprandial glucose reduction such as liraglutide or semaglutide.

1,5-AG below 6 µg/mL with HbA1c above 8.0%: Both markers are abnormal. 1,5-AG loses sensitivity at high HbA1c levels because the renal glucose threshold is exceeded so frequently that 1,5-AG is persistently depleted [1]. At this point, HbA1c and fasting glucose drive therapy escalation. The clinician may intensify basal insulin, add a second oral agent, or consider combination injectable therapy per ADA guidelines [3].

1,5-AG below 10 µg/mL after starting a new medication: A persistent low 1,5-AG after 4 to 6 weeks on a new drug suggests the agent is not adequately blunting postprandial spikes. This can prompt a dose increase, timing adjustment (taking the medication 15 to 30 minutes before meals rather than with meals), or switch to a different drug class.

How GLP-1 Receptor Agonists Affect Your GlycoMark

GLP-1 receptor agonists (GLP-1 RAs) directly reduce postprandial glucose through several mechanisms: enhanced glucose-dependent insulin secretion, suppressed glucagon release, and delayed gastric emptying. These actions make 1,5-AG a particularly useful monitoring tool during GLP-1 RA therapy.

In the LEAD-1 through LEAD-6 liraglutide trials, postprandial glucose reductions of 31 to 49 mg/dL were observed at the 1.8 mg dose [7]. A patient on liraglutide whose 1,5-AG remains below 10 µg/mL may not be achieving sufficient postprandial blunting, suggesting the need to add a mealtime strategy (prandial insulin, dietary carbohydrate redistribution) rather than simply increasing the GLP-1 RA dose.

Semaglutide shows even stronger postprandial glucose reduction. The SUSTAIN-1 trial (N=388) reported a 1.0 mg dose lowered postprandial glucose increments by approximately 35 to 57 mg/dL versus placebo at 30 weeks [8]. A clinician might order 1,5-AG at week 6 to 8 of semaglutide titration to confirm that spikes are resolving before the next HbA1c measurement is due.

Tirzepatide, the dual GIP/GLP-1 receptor agonist, produced postprandial glucose reductions of 55 to 65 mg/dL at the 15 mg dose in the SURPASS-1 trial (N=478) [9]. The speed of 1,5-AG recovery during tirzepatide titration can help clinicians decide whether to advance to the next dose or hold at the current one.

The SGLT2 Inhibitor Caveat: When GlycoMark Becomes Unreliable

SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) lower blood glucose by blocking renal glucose reabsorption in the proximal tubule. The same transporter (SGLT2) that reabsorbs glucose also reabsorbs 1,5-AG. Blocking it causes 1,5-AG to spill into the urine regardless of glycemic control [10].

The practical consequence is clear: 1,5-AG levels will be artificially low in any patient taking an SGLT2 inhibitor. A 2014 study by Fonseca et al. in Diabetes, Obesity and Metabolism measured 1,5-AG in patients on canagliflozin and found levels dropped to 1 to 3 µg/mL even in patients with excellent glycemic control and HbA1c below 6.5% [10]. The GlycoMark assay package insert explicitly states that 1,5-AG "should not be used to monitor glycemic control in patients taking SGLT2 inhibitors" [2].

If you are on dapagliflozin (Farxiga), empagliflozin (Jardiance), canagliflozin (Invokana), or the combination agents containing these drugs, your clinician will rely on CGM data, fructosamine, or time-in-range metrics rather than 1,5-AG for postprandial assessment.

Other Conditions That Alter 1,5-AG Independently of Glucose Control

Several non-glycemic conditions affect 1,5-AG interpretation.

Chronic kidney disease (CKD). Reduced glomerular filtration lowers 1,5-AG by decreasing tubular reabsorption capacity. A study by Yamanouchi et al. demonstrated that 1,5-AG declines progressively as eGFR falls below 60 mL/min/1.73 m² [11]. In stage 3B or worse CKD, 1,5-AG results should be interpreted cautiously or avoided entirely.

Pregnancy. Physiologic changes in renal threshold during pregnancy lower 1,5-AG. Research published in the Journal of Diabetes Science and Technology found that 1,5-AG was significantly lower in pregnant women without diabetes compared to non-pregnant controls, limiting its utility for gestational diabetes monitoring [12].

Liver cirrhosis. Severe hepatic impairment reduces 1,5-AG synthesis and storage, producing falsely low values. Clinicians managing diabetes in cirrhotic patients typically rely on fructosamine or glycated albumin instead.

Gastrectomy or malabsorption. Because dietary intake contributes to 1,5-AG steady-state levels, patients who have undergone gastric bypass or who have celiac-related malabsorption may have lower baseline 1,5-AG [1].

How to Raise a Low GlycoMark (Improve Your 1,5-AG)

Raising 1,5-AG means reducing the frequency and severity of glucose excursions above 180 mg/dL. There is no supplement or direct pharmacologic way to raise 1,5-AG itself. The number improves only when postprandial glucose control improves. Here are the evidence-based strategies.

Carbohydrate distribution. Spreading carbohydrate intake across 3 to 4 smaller meals rather than concentrating it in 1 to 2 large meals reduces peak postprandial glucose. The ADA nutrition therapy consensus report recommends individualized carbohydrate distribution as a first-line dietary strategy [13].

Meal sequencing. A 2015 study by Shukla et al. published in Diabetes Care showed that eating protein and vegetables before carbohydrates in the same meal reduced postprandial glucose by 28.6% (73.2 vs. 54.2 mg/dL peak incremental change) in patients with type 2 diabetes [14].

Medication timing. Taking rapid-acting insulin 15 to 20 minutes before meals instead of at the start of the meal reduces postprandial peaks. For patients on sulfonylureas, switching to a shorter-acting agent (glipizide instead of glimepiride) may provide better mealtime coverage.

Adding acarbose. Acarbose 50 to 100 mg taken with the first bite of a meal inhibits alpha-glucosidase enzymes in the small intestine, slowing carbohydrate digestion and flattening the postprandial glucose curve. The STOP-NIDDM trial (N=1,429) showed acarbose reduced 2-hour postprandial glucose by approximately 0.6 mmol/L [15].

Exercise timing. A 15- to 20-minute walk after meals reduces postprandial glucose more than the same walk taken before eating. A meta-analysis published in Sports Medicine (2022) confirmed that post-meal walking reduced postprandial glucose by an average of 17% compared to prolonged sitting [16].

What a Trending 1,5-AG Tells Your Doctor Over Time

A single 1,5-AG value provides a snapshot, but serial measurements reveal trajectory. Because 1,5-AG reflects only the prior 1 to 2 weeks, it responds to treatment changes faster than HbA1c, which lags by 8 to 12 weeks.

Dr. David Sacks, co-author of the National Academy of Clinical Biochemistry guidelines on diabetes laboratory testing, has stated: "1,5-AG provides a short-term marker of glycemic excursions that complements HbA1c by capturing information about glucose variability that other tests miss" [17].

The AACE/ACE 2023 consensus algorithm for type 2 diabetes management recommends considering "markers of glycemic variability, including 1,5-AG, when evaluating the adequacy of postprandial glucose control, particularly in patients with cardiovascular risk" [6]. This recommendation positions 1,5-AG as part of a composite assessment rather than a standalone test.

A practical monitoring cadence: measure 1,5-AG at baseline, repeat 4 to 6 weeks after any medication or lifestyle intervention targeting postprandial glucose, and again at 12 weeks alongside HbA1c. If 1,5-AG rises by 3 or more µg/mL, the intervention is reducing spike frequency. If it remains flat or drops, the clinician should reassess the approach.

The Endocrine Society's 2022 clinical practice guideline on CGM use notes that 1,5-AG may serve as a surrogate for CGM-derived metrics in settings where CGM is unavailable or not covered by insurance [18]. For patients without CGM access, a quarterly 1,5-AG paired with HbA1c gives the closest laboratory approximation of both mean glucose and glucose variability.

Patients taking metformin as monotherapy who have an HbA1c of 6.8% but a 1,5-AG of 7.2 µg/mL should discuss adding a GLP-1 RA or a DPP-4 inhibitor with their prescriber, as these agents specifically target the incretin pathway that governs postprandial insulin release [3].